Select a community
Parkinson's
Find out more about the PatientsLikeMe
Parkinson's Community
Home > Community Treatment Reports > Celebrex Treatment Report
What is Celebrex?

Celebrex is the brand name for celecoxib, a non-steroidal antiinflammatory used to relieve the pain, swelling and stiffness of osteoarthritis and adult rheumatoid arthritis; to treat of primary dysmenorrhea; and to reduce intestinal polyps in the inherited disorder adenomatous polyposis.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Other 4 1
Arthritis 2 0
General health 2 0
Mobility 2 1
joint pain 2 1
Pain 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
3 100%

Dosages

  20 mg daily 50 mg daily 100 mg daily 200 mg daily 400 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 6 Number of Patients: 6 2 Number of Patients: 2  

Stop Reasons

Why Patients Stopped Taking Celebrex (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
2 50% Other: 50%
Did not seem to work
1 25% Did not seem to work: 25%
Expense
1 25% Expense: 25%
Side effects too severe
1 25% Side effects too severe: 25%

See all 4 patients who’ve stopped taking Celebrex

Currently Taking Celebrex

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
1
5

Stopped Taking Celebrex

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
2
1
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
3 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
3 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
2 67%
$25-49
1 33%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.